(PRPO) – Company Press Releases
-
Precipio Announces Year end 2023 Shareholder Update Call
-
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
-
Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer
-
Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
-
Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan
-
Precipio Announces Christina Valauri joins the Board of Directors
-
Precipio Announces Q3-2023 Shareholder Update Call
-
Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022
-
Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023
-
Precipio Continues to Sign New HemeScreen™ Customers
-
Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven
-
Precipio’s Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan
-
Precipio Announces Q2-2023 Shareholder Update Call
-
Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel
-
Precipio’s Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven
-
Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023
-
Precipio’s Omnia™ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy
-
Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology
-
Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
-
Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects
-
Precipio’s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology
-
Precipio Shares Growth Catalysts For HemeScreen
-
Precipio Announces Q1-2023 Shareholder Update Call
-
Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division
-
Precipio Signs Another HemeScreen™ Customer
-
Precipio Granted 180-day Extension From NASDAQ To Regain Compliance
-
Precipio Unaudited Q1-2023 Product Revenues Exceed The Two Prior Quarters (Q3+Q4 of 2022) Combined
-
Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call
-
Precipio Ships First IV-Cell® Order to Major US Healthcare System
-
CORRECTION -- Precipio continues to sign up and onboard HemeScreen™ customers
-
Precipio continues to sign up and onboard HemeScreen™ customers
-
ThermoFisher Salesforce Votes Precipio’s HemeScreen® as “Best New Product”
-
Precipio Signs Another Major HemeScreen™ Customer
-
Precipio Signs Additional Major HemeScreen™ Customer
-
Precipio Presents Poster on HemeScreen® Study at Association of Molecular Pathology (AMP) 2022 Annual Conference
-
Precipio Announces Third Quarter Shareholder Update Call
-
Precipio Signs Agreement with Another Major US Healthcare Distributor for HemeScreen™
-
Sharon Robins Joins Precipio’s Products Division as Senior Director of Laboratory & Hospital Sales
-
Precipio Launches New 1-Step Technology for all HemeScreen Assays
-
Toni-Ann Mills Joins Precipio’s Products Division to Lead Channel Partner Training, Learning & Development
-
Precipio Announces Second Quarter Shareholder Update Call
-
Precipio to distribute HemeScreen® through Fisher Healthcare channel
-
Precipio requests that all Stockholders that have not yet voted, proceed to cast their vote
-
Keith Meadors Joins Precipio to Lead its Products Division
-
Precipio Receives CE-IVD Certification to Market Multiple HemeScreen® Panels in Europe
-
Precipio Signs First IV-Cell Customer Agreement
-
Precipio customer American Oncology Network (AON) selected to present HemeScreen® technology case study at Industry leading clinical laboratory conference
-
Precipio Announces 2021 Fourth Quarter and Year-End Shareholder Update Call
-
Precipio Inc. Announces the Resignation of its Chief Financial Officer and Appointment of Interim CFO
-
Precipio Releases Year-End 2021 Preliminary Unaudited Results and Outlook for 2022
Back to PRPO Stock Lookup
